Sanofi’s efanesoctocog alfa may be game-changer for haemophilia A patients
Phase 3 study demonstrated that efanesoctocog alfa met both primary and secondary endpoints
Read More
Tag: efanesoctocog
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
